In AD models, depleting microglial cells by pharmacologically inhibiting CSF1R reduces pro-inflammatory signaling and rescues tau pathology, while also protecting against neuroinflammation and dopaminergic neurodegeneration in PD models16,17. Here, MAPT is linked to Alzheimer disease.